Evidence map›Paper›PMID 26346163›Full record

ArticleMolecular and cellular biochemistry2015

Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells.

Fredrick J Bohanon, Xiaofu Wang, Brittany M Graham, Anesh Prasai, Sadhashiva J Vasudevan, Chunyong Ding, Ye Ding, Geetha L Radhakrishnan, Cristiana Rastellini, Jia Zhou and 1 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Design and synthesis of novel oridonin analogues as potent anticancer agents.Journal of enzyme inhibition and medicinal chemistry · 2018
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.International journal of molecular sciences · 2016
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fredrick J BohanonDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Xiaofu WangDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Brittany M GrahamDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Anesh PrasaiDepartment of Cell Biology and Neuroscience, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Sadhashiva J VasudevanDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Chunyong DingChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Ye DingChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Geetha L RadhakrishnanDepartment of Pediatrics, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Cristiana RastelliniDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA.
Jia ZhouChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA. jizhou@utmb.edu.
Ravi S RadhakrishnanDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555, USA. rsradhak@utmb.edu.
The University of Texas Medical Branch at Galveston · USShriners Hospitals for Children - Galveston · US

Funding

Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LEE, J. JACK · 2002 to 2012
$26.1M
POSTDOCTORAL TRAINING IN TRAUMA &BURNST32GM008256 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Celeste Campbell Finnerty, Oscar E. Suman-Vejas · 1990 to 2026
$4.0M
Core Center for Translational Addiction SciencesP30DA028821 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2009 to 2010
$1.5M
Optimization of Allosteric Modulators of 5-HT2C ReceptorR21MH093844 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A., ZHOU, JIA · 2012 to 2013
$450k
NCI NIH HHS P50 CA097007NIDA NIH HHS P30 DA028821NIGMS NIH HHS T32 GM008256NIGMS NIH HHS T32-GM8256NIMH NIH HHS R21 MH093844
6 · The paper itself

Abstract

Oridonin, isolated from Rabdosia rubescens, has been proven to possess various anti-neoplastic and anti-inflammatory properties. Previously, we reported the anti-fibrogenic effects of oridonin for liver in vitro. In the present study, we investigated the effects of a newly designed analog CYD0692 in vitro. Cell viability was measured by Alamar Blue assay. Cell apoptosis was assessed by Cell Death ELISA and Yo-Pro-1 staining. Western blots were performed for cellular proteins. Flow cytometry was used to measure cell cycle regulation. CYD0692 significantly inhibited LX-2 cells proliferation in a dose- and time-dependent manner with an IC50 value of ~0.7 μM for 48 h, ~tenfold greater potency than oridonin. Similar results were observed in HSC-T6 cells. In contrast, on the human hepatocyte cell line C3A, only 12 % of the cell growth was inhibited with 5 μM of CYD0692 treatment for 48 h, while 30 % inhibited at 10 μM. After CYD0692 treatment on LX-2 cells, apoptosis and S-phase cell cycle arrest were induced; cleaved-PARP, p21, and p53 were activated while cyclin-B1 levels declined. In addition, α-smooth muscle actin, type I Collagen, and fibronectin (FN) were markedly down regulated. Transforming growth factor β1 (TGF β1) has been identified as a dominant stimulator for ECM production in HSC. Our results indicated that pretreatment with CYD0692 blocked TGF β1-induced FN expression, thereby decreasing the downstream factors of TGF β1 signaling, such as Phospho-Smad2/3 and phospho-ERK. In comparison with oridonin, its novel derivative CYD0692 has demonstrated to be a more potent and potentially safer anti-fibrogenic agent for the treatment of hepatic fibrosis.

Indexed as

AnimalsApoptosisApoptosis Regulatory ProteinsCell Cycle ProteinsCell LineCell ProliferationDiterpenes, KauraneDose-Response Relationship, DrugExtracellular MatrixHepatic Stellate CellsHumansInhibitory Concentration 50Liver CirrhosisRatsS Phase Cell Cycle CheckpointsTime FactorsApoptosis Regulatory ProteinsCell Cycle ProteinsCYD0682Diterpenes, KauraneoridoninApoptosisECMLiver fibrosisOridoninStellate cells

Identifiers

PMID26346163
PMCPMC5665655
OpenAlexW1842563274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.